Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3265738 | 0.84 | MEN1 (0.58) | MAPK10CDK1KDRCDK2LMNA | |
| SCHEMBL13750837 | 0.82 | HTT (0.59) | HTTLRRK2CCNA2CDK2CDK5 | |
| SCHEMBL4491188 | 0.80 | HTT (0.62) | HTTMAPK10CCNB2CDK1RET | |
| SCHEMBL29430401 | 0.80 | HTT (0.62) | HTTMAPK10CCNB2CDK1RET | |
| SCHEMBL28734979 | 0.79 | MAPK10 (0.51) | HTTMAPK10CCNB2CDK1RET | |
| SCHEMBL31220877 | 0.79 | MAPK10 (0.73) | HTTMAPK10PTK2KDRCCNA2 | |
| SCHEMBL7941542 | 0.79 | MAPK10 (0.73) | HTTMAPK10PTK2KDRCCNA2 | |
| SCHEMBL7982557 | 0.79 | NPC1 (0.52) | HTTMAPK10KDRCCNA2CDK2 | |
| SCHEMBL30114717 | 0.79 | HSD17B10 (0.59) | HTTKDRLMNANPC1RAB9A | |
| SCHEMBL29511793 | 0.78 | HTT (0.59) | HTTMAPK10ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3613504-A1 | PI-ALLYLPALLADIUM AND PI-ALLYLNICKEL COMPLEXES FOR USE AS CATALYSTS IN CARBON-CARBON AND CARBON-NITROGEN COUPLING REACTIONS | Johnson Matthey Public Limited Company (GB) | 2020-02-26 | — | — | EP | disclosed |
| EP-2585216-B1 | PI-ALLYLPALLADIUM AND PI-ALLYLNICKEL COMPLEXES FOR USE AS CATALYSTS IN CARBON-CARBON AND CARBON-NITROGEN COUPLING REACTIONS | JOHNSON MATTHEY PLC (GB) | 2019-11-20 | — | — | EP | disclosed |
| CN-107721991-B | A kind of 6- (pyrimidine-4-yl) -1H- indazole derivative and its preparation method and application | 南方医科大学中西医结合医院 | 2019-10-18 | — | — | CN | disclosed |
| US-10167305-B2 | Allyl complexes for use in coupling reactions | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2019-01-01 | — | — | US | disclosed |
| CN-107721991-A | A kind of 6 (base of pyrimidine 4) 1H indazole derivatives and its preparation method and application | 南方医科大学中西医结合医院 | 2018-02-23 | — | — | CN | disclosed |
| US-20130165660-A1 | COMPLEXES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2013-06-27 | — | — | US | disclosed |
| EP-2585216-A1 | COMPLEXES | Johnson Matthey PLC (GB) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011161451-A1 | COMPLEXES | JOHNSON MATTHEY PLC (GB) | 2011-12-29 | — | — | WO | disclosed |
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | PALAU PHARMA, S.A. (ES) | 2009-12-10 | — | — | US | disclosed |
| WO-2009029617-A1 | DIARYLAMINE-SUBSTITUTED QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-0233461-B2 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID CO (US) | 2002-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167305-B2 | Allyl complexes for use in coupling reactions | AP3M1, AP1M1, C9 | HTT 4759/4885MAPK10 2748/4885CCNB2 653/4885 |
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | HRH4, HRH2, HRH3 | HTT 1416/4885MAPK10 4046/4885CCNB2 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.